Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipid profile changes after switching from protease inhibitor-based to dolutegravir-based second-line ART in people living with HIV
TCTR20240717004Completed
- Sponsor
- Faculty of Medicine, Chulalongkorn University
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Faculty of Medicine, Chulalongkorn University. Primary endpoint: Change in lipid profile after switching to dolutegravir-based regimen. Started Jul 2019; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on TCTR20240717004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240717004.